| 吉非替尼治疗非小细胞肺癌的临床疗效观察 |
| 投稿时间：2007-09-05 点此下载全文 |
| 引用本文：贾国强,杨亚青.吉非替尼治疗非小细胞肺癌的临床疗效观察[J].药学实践杂志,2007,(6):399~400 |
| 摘要点击次数: 809 |
| 全文下载次数: 38 |
|
|
| 中文摘要:目的:分析吉非替尼治疗非小细胞肺癌的临床疗效。方法:调查我院2005年1月到2006年12月患非小细胞肺癌的住院病人40例,给予吉非替尼250 mg,每日1次口服。结果:总有效率为35.0%(完全缓解1例,部分缓解13例),疾病控制率为82.5%(完全缓解1例,部分缓解13例,基本稳定19例)。其中男性病人29例,女性病人11例,有效率分别为55.2%和36.4%(P<0.05)。主要不良反应是恶心呕吐37%、厌食25%、皮疹18%等。结论:吉非替尼治疗非小细胞肺癌有较好的疗效,不良反应较轻,可以提高大多数病人的生活和生存质量。 |
| 中文关键词:吉非替尼 非小细胞肺癌 疗效分析 |
| |
| Clinical curative effect analysis of gefitinib for treat NSCLC |
|
|
| Abstract:Objective:To analyze clinical curative effect of Gefitinib to treat NSCLC(non-small cell lung cancer).Methods:40 cases in-patient with NSCLC in Hospital of PLA General Hospital during Juan 2005 to Dec 2006,were administrated Gefitinib 250 mg daily orally,and investigated for it's curative effect.Results:The total effective rate was 35.0%,CR(complete remission)1 case,PR(partial remission) 13 cases,the disease control rate was 82.5%(CR was 1 case,PR was 13 cases,basio-stabilization was 19 cases).There were 29 male patients and 11 females,and effective rate were 55.2% and 36.4% respectively(P<0.05).The main adverse reaction were nausea and vomiting(37%),anorexy(25%),and exanthem(18%).Conclusion: Gefitinib has a better curative effect to treat NSCLC,and the adverse effect is gently,it can improve majority patient quality of life and survival. |
| keywords:Gefitinib non-small cell lung cancer(NSCLC) clinical curative effect analysis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
